Skip Navigation

European Heart Journal 1995 16(Supplement L):11-15; doi:10.1093/eurheartj/16.suppl_L.11
Copyright © 1995 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Coller, B. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coller, B. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1995 The European Scociety of Cardiology

The role of platelets in arterial thrombosis and the rationale for blockade of platelet GPIIb/IIIa receptors as antithrombotic therapy

B. S. Coller

Department of Medicine The Mount Sinai Medical Center New York, U.S.A

Correspondence: Barry S Coller, MD, Department of Medicine, The Mount Sinai Medical Center, Box 1118, New York, NY, 10029-6574, U.S.A

Platelet aggregation plays a crucial role in ischaemic arterial thrombosis. Recent biochemical data indicate that the platelet glycoprotein (GP) IIb/IIIa receptor mediates platelet aggregation by binding fibrinogen, von Willebrand factor, or other ligands, that can span between platelets. New antiplatelet agents that block the binding sites on GPIIb/IIIa are efficacious in arterial thrombosis animal models and are now being evaluated in human disease. A mouse/human chimeric monoclonal antibody fragment (c7E3 Fab) and agents modelled after the arginine-glycine-aspartic acid (RGD) cell binding motif are in development. c7E3 Fab showed significant efficacy in reducing ischaemic complications after angioplasty in patients at high risk of such complications in the EPIC study, and thus has been approved for use in the U.S. and several European and Scandinavian countries. These new agents also hold considerable promise in the treatment of other thrombotic disorders, including unstable angina and myocardial infarction.

Key Words: Platelet • glycoprotein IIb/IIIa • thrombosis • angioplasty


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.